| Quartiles of serum GPx3 activity (units/L) | Continuous (per 100 units/L) |
<589 | 589-655 | 655-715 | ≥715 |
Cases/controls (n) | 70/121 | 65/125 | 48/123 | 65/123 | 0.29 |
| | 0.57 | 0.07 | 0.68 | 0.93 |
Crude OR* (95% CI) | 1.00 | 0.89 (0.58, 1.35) | 0.67 (0.43, 1.04) | 0.92 (0.60, 1.40) | (0.81, 1.07) |
| | 0.36 | 0.05 | 0.46 | 0.17 |
Adjusted OR† (95% CI) | 1.00 | 0.82 (0.53, 1.26) | 0.63 (0.39, 0.99) | 0.85 (0.55, 1.31) | 0.91 (0.79, 1.04) |
Excluding cases diagnosed during 1st year of follow-up (and matched controls) |
Cases/controls (n) | 68/116 | 63/116 | 44/119 | 60/155 | |
Adjusted OR† (95% CI) | 1.00 | 0.84 (0.54, 1.31) | 0.59 (0.36, 0.94) | 0.83 (0.53, 1.30) | 0.88 (0.76, 1.02) |
High-grade prostate cancer |
Cases/controls (n) | 27/45 | 26/48 | 21/44 | 18/45 | |
Adjusted OR† (95% CI) | 1.00 | 0.86 (0.43, 1.73) | 0.82 (0.41, 1.65) | 0.68 (0.33, 1.40) | 0.85 (0.67, 1.09) |
Low-grade prostate cancer |
Cases/controls (n) | 39/66 | 32/65 | 23/66 | 36/61 | |
Adjusted OR† (95% CI) | 1.00 | 0.74 (0.40, 1.36) | 0.50 (0.25, 0.99) | 0.80 (0.42, 1.52) | 0.90 (0.74, 1.10) |